Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Marvel Biosciences (OTCQB: MBCOF) has secured a significant patent in China for its lead therapeutic candidate MB-204, a novel fluorinated derivative of Istradefylline. The patent (ZL202180020893.4) covers the compound's composition of matter, which is designed to target autism spectrum disorder and related conditions.
MB-204 has demonstrated enhanced potency, longer duration, and improved tolerability in preclinical studies, showing efficacy in models of autism, Rett syndrome, and depression. The company is preparing to advance the drug candidate into Phase 1 clinical trials, addressing a significant market need with approximately 1 in 36 children diagnosed with autism.
Marvel Biosciences (OTCQB: MBCOF) ha ottenuto un importante brevetto in Cina per il suo principale candidato terapeutico, MB-204, un nuovo derivato fluorurato dell'Istradefillina. Il brevetto (ZL202180020893.4) protegge la composizione della sostanza, concepita per intervenire nei disturbi dello spettro autistico e patologie correlate.
Negli studi preclinici MB-204 ha mostrato una maggiore potenza, durata d'azione prolungata e migliore tollerabilità, dimostrando efficacia in modelli di autismo, sindrome di Rett e depressione. L'azienda si prepara a portare il candidato in trial clinici di Fase 1, rispondendo a un'esigenza di mercato significativa: circa 1 bambino su 36 è diagnosticato con autismo.
Marvel Biosciences (OTCQB: MBCOF) ha asegurado una patente relevante en China para su principal candidato terapéutico, MB-204, un nuevo derivado fluorinado de la Istradefilina. La patente (ZL202180020893.4) cubre la composición de la sustancia, diseñada para actuar sobre el trastorno del espectro autista y afecciones relacionadas.
En estudios preclínicos MB-204 ha demostrado mayor potencia, duración prolongada y mejor tolerabilidad, mostrando eficacia en modelos de autismo, síndrome de Rett y depresión. La compañía se prepara para avanzar el fármaco a ensayos clínicos de Fase 1, atendiendo una necesidad de mercado significativa: aproximadamente 1 de cada 36 niños está diagnosticado con autismo.
Marvel Biosciences (OTCQB: MBCOF)는 주력 치료 후보물질 MB-204에 대해 중국에서 주요 특허를 확보했습니다. MB-204는 이스트라데필린의 새로운 플루오린화 유도체이며, 특허(ZL202180020893.4)는 이 화합물의 조성물을 보호하며 자폐 스펙트럼 장애 및 관련 질환을 표적으로 합니다.
전임상 연구에서 MB-204는 향상된 효능, 더 긴 지속성, 개선된 내약성을 보였고 자폐증, 레트 증후군, 우울증 모델에서 유효성을 입증했습니다. 회사는 이 후보물질을 1상 임상시험으로 진전시키기 위해 준비 중이며, 약 36명 중 1명의 아동이 자폐 진단을 받는 중요한 시장 수요에 대응하고자 합니다.
Marvel Biosciences (OTCQB: MBCOF) a obtenu un brevet important en Chine pour son principal candidat thérapeutique, MB-204, un nouveau dérivé fluoré de l'Istradefylline. Le brevet (ZL202180020893.4) couvre la composition de la molécule, conçue pour cibler les troubles du spectre autistique et affections connexes.
En études précliniques, MB-204 a montré une puissance accrue, une durée d'action prolongée et une meilleure tolérance, démontrant une efficacité dans des modèles d'autisme, du syndrome de Rett et de dépression. La société se prépare à faire progresser le candidat en essais cliniques de phase 1, répondant à un besoin de marché significatif : environ 1 enfant sur 36 est diagnostiqué autiste.
Marvel Biosciences (OTCQB: MBCOF) hat in China ein bedeutendes Patent für seinen führenden Wirkstoffkandidaten MB-204 gesichert, einen neuartigen fluorierten Derivat der Istradefyllin. Das Patent (ZL202180020893.4) deckt die Zusammensetzung der Verbindung ab, die auf Autismus-Spektrum-Störungen und verwandte Erkrankungen abzielt.
In präklinischen Studien zeigte MB-204 erhöhte Wirksamkeit, längere Wirkungsdauer und bessere Verträglichkeit und erzielte positive Ergebnisse in Modellen von Autismus, Rett-Syndrom und Depression. Das Unternehmen bereitet den Übergang des Kandidaten in Phase-1-Studien vor und adressiert damit einen bedeutenden Marktbedarf: etwa 1 von 36 Kindern erhält eine Autismus-Diagnose.
- Patent granted in China strengthens global intellectual property position
- MB-204 showed strong preclinical efficacy across multiple disease models
- Drug candidate ready to enter Phase 1 clinical trials
- Enhanced drug properties including superior potency and improved tolerability
- None.
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders". The patent covers the composition of matter for Marvel's lead asset, MB-204.
MB-204 is a novel, fluorinated derivative of the adenosine A2A receptor antagonist Istradefylline, engineered for superior potency, longer duration, and improved tolerability. It has demonstrated strong preclinical efficacy across multiple models of autism, Rett syndrome, and depression, and is ready to enter Phase 1 clinical trials.
"This allowance further strengthens our global IP position in a key market," said J. Roderick Matheson, CEO of Marvel Biosciences. "Securing these rights is an important step, and we look forward to achieving similar outcomes in other key jurisdictions". With approximately one in 36 children diagnosed with autism, there is a clear need for innovation. "We remain committed to advancing MB-204 through the clinic to address these significant unmet medical needs."
About Marvel Biosciences Corp.
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.
Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262961
FAQ
What patent did Marvel Biosciences (MBCOF) receive in China?
What conditions is Marvel Biosciences' MB-204 designed to treat?
What are the key advantages of Marvel Biosciences' MB-204 drug candidate?
What is the current development stage of Marvel Biosciences' MB-204?
What is the market potential for Marvel Biosciences' autism treatment?
